Neurocrine Biosciences (NBIX) Revenue (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Revenue (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.74% |
| Mar 31, 2026 | 1.12% |
| Dec 31, 2025 | 1.33% |
| Sep 30, 2025 | 15.62% |
| Jun 30, 2025 | 20.07% |
| Mar 31, 2025 | -8.78% |
| Dec 31, 2024 | 0.90% |
| Sep 30, 2024 | 5.40% |
| Jun 30, 2024 | 14.54% |
| Mar 31, 2024 | 0.02% |
| Dec 31, 2023 | 3.29% |
| Sep 30, 2023 | 10.18% |
| Jun 30, 2023 | 7.68% |
| Mar 31, 2023 | 2.04% |
| Dec 31, 2022 | 6.21% |
| Sep 30, 2022 | 2.56% |
| Jun 30, 2022 | 21.76% |
| Mar 31, 2022 | -0.45% |
| Dec 31, 2021 | 5.41% |
| Sep 30, 2021 | 2.46% |